CRSP — CRISPR Therapeutics AG
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1674416 ·
Switzerland
Last close
$47.99
Market Cap
$4.73B
52W High
$63.45
52W Low
$45.89
ADV30
1,729,317
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,000,000 | -44,949,000 | -130,248,000 | -122,931,000 | 2,725,820,000 | 423,308,000 | 911,264,000 |
| Dec 2025 | 0 | -53,703,000 | -154,764,000 | -130,613,000 | 2,265,243,000 | 347,559,000 | 343,430,000 |
| Sep 2025 | 0 | -57,115,000 | -132,059,000 | -106,441,000 | 2,245,308,000 | 286,497,000 | 329,326,000 |
| Jun 2025 | 0 | -45,153,000 | -229,324,000 | -208,549,000 | 2,029,711,000 | 193,618,000 | 318,586,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-399,964,000
Investing CF
$-422,793,000
Financing CF
$1,007,346,000
CapEx
$-26,212,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.22
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,070,482,000
Inventory
—
Receivables
—
ST Investments
$2,018,477,000
EBIT TTM
$-646,395,000
Pretax Income TTM
$-565,170,000
Interest Exp TTM
—
Analysts
21
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,103,000
EBITDA
$-531,080,000
Free Cash Flow
$-260,895,744
Enterprise Value
$2,974,434,560
Total Cash
$2,441,785,088
Total Debt
$787,641,984
Shares Out
98,484,128
Trailing EPS
$-6.17
Book Value
$18.83
ROE
-31.2%
ROA
-14.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -664,571,000 | -581,599,000 | 2,265,243,000 | 343,430,000 | — | -345,014,000 |
| Dec 2024 | 35,000,000 | -466,566,000 | -366,252,000 | 2,242,034,000 | 309,954,000 | — | -142,774,000 |
| Dec 2023 | 370,000,000 | -222,538,000 | -153,610,000 | 2,229,571,000 | 346,768,000 | — | -260,375,000 |
| Dec 2022 | 436,000 | -673,161,000 | -650,175,000 | 2,243,057,000 | 367,578,000 | — | -495,741,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | $4.10B | $18.83 | — |
| SRRK | Scholar Rock Holding Corp | $5.67B | $47.29 | — |
| TWST | Twist Bioscience Corp | $5.70B | $91.55 | — |
| DNLI | Denali Therapeutics Inc. | $3.65B | $23.02 | — |
| ADPT | Adaptive Biotechnologies Corp | $3.59B | $22.57 | — |
News headlines (Yahoo Finance, 1h cache)
CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?
2026-08-01 11:15 · Yahoo
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
2026-07-30 21:58 · Yahoo
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
2026-07-30 21:50 · Yahoo
3 Stocks With the Most Upside by the End of 2026
2026-07-30 20:50 · Yahoo
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
2026-07-30 14:26 · Yahoo
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside
2026-07-28 15:22 · Yahoo
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
2026-07-28 14:00 · Yahoo
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
2026-07-28 13:00 · Yahoo
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-07-27 14:00 · Yahoo
Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.
2026-07-27 09:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.